Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Prosthetic Joint infections - Overview
Prosthetic Joint infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Prosthetic Joint infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prosthetic Joint infections - Companies Involved in Therapeutics Development
Armata Pharmaceuticals Inc
Arrevus Inc
ContraFect Corp
Lumobiotics GmbH
Peptilogics Inc
Sonoran Biosciences Inc
Telephus Medical LLC
TenNor Therapeutics Ltd
Prosthetic Joint infections - Drug Profiles
(tobramycin + vancomycin SR) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APSA-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APSA-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-296 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exebacase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fusidic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLG-0206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Oncology and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNP-2092 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPH-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prosthetic Joint infections - Dormant Projects
Prosthetic Joint infections - Discontinued Products
Prosthetic Joint infections - Product Development Milestones
Featured News & Press Releases
Feb 25, 2020: Peptilogics announces CARB-X funding to accelerate development of first-in-class antibiotics to address the global threat of multi-drug resistant bacteria
Jan 20, 2020: TenNor Therapeutics received FDA orphan drug desigtion
Jan 13, 2020: ContraFect partners with leading orthopedic center in Europe to provide compassiote use of exebacase to patients with chronic staphylococcal prosthetic joint infections
Oct 15, 2018: Peptilogics receives regulatory approval to initiate first-in-human safety study for therapeutic peptide PLG0206
Aug 24, 2018: Peptilogics completes successful pre-IND meeting with the Food and Drug Administration for PLG0206 in Prosthetic Joint Infections
Jun 02, 2018: Peptilogics Receives Qualified Infectious Disease Product Desigtion from FDA for Lead Compound PLG0206 as a Treatment for Prosthetic Joint Infection
Oct 29, 2013: Cempra Receives U.S. Orphan Drug Desigtion for Taksta for Treatment of Prosthetic Joint Infections
Dec 14, 2012: Cempra Announces Initiation Of CEM-102 Phase II Clinical Trial In Patients With Prosthetic Joint Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Prosthetic Joint infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Prosthetic Joint infections, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Prosthetic Joint infections - Pipeline by Armata Pharmaceuticals Inc, H1 2020
Prosthetic Joint infections - Pipeline by Arrevus Inc, H1 2020
Prosthetic Joint infections - Pipeline by ContraFect Corp, H1 2020
Prosthetic Joint infections - Pipeline by Lumobiotics GmbH, H1 2020
Prosthetic Joint infections - Pipeline by Peptilogics Inc, H1 2020
Prosthetic Joint infections - Pipeline by Sonoran Biosciences Inc, H1 2020
Prosthetic Joint infections - Pipeline by Telephus Medical LLC, H1 2020
Prosthetic Joint infections - Pipeline by TenNor Therapeutics Ltd, H1 2020
Prosthetic Joint infections - Dormant Projects, H1 2020
Prosthetic Joint infections - Discontinued Products, H1 2020